

## Program Agenda - Friday, November 16, 2018

---

- 7:30 – 8:00 am      **Continental Breakfast**
- 8:00 – 8:10 am      **Opening Remarks**  
*Michael Birrer, M.D., Ph.D., Director, UAB Comprehensive Cancer Center*
- 8:15 – 9:00 am      **Alex Adjei, M.D., Ph.D. (35 min. + 10 min. of Q & A)**  
Professor of Oncology and Pharmacology, Consultant, Medical Oncology  
Mayo College of Medicine  
*Precision Medicine in 2018: Successes and Challenges*
- 9:05 – 10:35 am      **Poster Session 1 (1 hr. 30 min.)**
- 10:40 – 11:05 am      **Tyler McCaw (25 min.)**  
UAB Medical Scientist Training Program  
*Appropriately timed histone deacetylase inhibition empowers T cell-mediated immunity to reject established breast tumors in pre-clinical models*
- 11:10 – 11:35 am      **Luciano Costa, M.D., Ph.D. (25 min.)**  
Associate Professor, Department of Medicine, UAB  
*Upfront chemo-immunotherapy and autologous hematopoietic cell transplantation followed by MRD-based response-adapted therapy in newly diagnosed multiple myeloma*
- 11:40-1:30 pm      **Poster Session 2 and Lunch (1hr. 50 min.)**
- 1:35 – 2:20 pm      **Laura Esserman, M.D., MBA (35 min. + 10 min. of Q & A)**  
Director, Carol Franc Buck Breast Care Center, Professor, Departments of Surgery and Radiology, University of California San Francisco  
*The Inflection Point in Early Breast Cancer: Refining Drug Development to Optimize Individual Outcomes*
- 2:25– 2:50 pm      **Adam Keeton, Ph.D. (25 min.)**  
Research Assistant Professor of Oncologic Sciences  
University of South Alabama Mitchell Cancer Institute  
*Novel RAS inhibitor MCI-062 potently and selectively inhibits the growth of KRAS mutant pancreatic tumor cells by blocking GTP loading of RAS*
- 2:55 – 3:20 pm      **Kaitlyn Dorsett (25 min.)**  
Graduate Student, Department of Cell, Developmental, & Integrative Biology, UAB  
*Sox2 drives ST6Gal-I expression and activity to promote a CSC phenotype in ovarian cancer*
- 3:25 – 3:50 pm      **Ravi Kumar Paluri, MBBS, MPH (25 min.)**  
Assistant Professor, Department of Medicine, UAB  
*UAB CCC first-in-human Phase 1 clinical trials- a 2 year experience*
- 3:55 – 4:20 pm      **Darshan Chandrashekar, Ph.D. (25 min.)**  
Postdoctoral Fellow, Department of Pathology, UAB  
*UALCAN: An integrated data-mining platform to facilitate the comprehensive analysis of cancer transcriptome*
- 4:25 – 5:00 pm      **Presentation of Awards (35 min.)**